<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36532316</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1172-0360</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>2</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Drugs &amp; therapy perspectives : for rational drug selection and use</Title><ISOAbbreviation>Drugs Ther Perspect</ISOAbbreviation></Journal><ArticleTitle>Antidepressants with anti-inflammatory properties may be useful in long COVID depression.</ArticleTitle><Pagination><StartPage>65</StartPage><EndPage>70</EndPage><MedlinePgn>65-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40267-022-00975-x</ELocationID><Abstract><AbstractText>Long COVID, which is characterised by the presence of persistent symptoms following a COVID infection, may also cause long COVID depression (LCD). Although the risk factors for LCD are not directly characterised, prior mental health visits were associated with an increased risk for long COVID, whereas antidepressant use was not. Current evidence suggests that pro-inflammatory factors in the brain are linked to LCD, thus anti-inflammatory agents may be useful in mitigating LCD. Limited evidence suggests that selective serotonin reuptake inhibitors may also be effective in the treatment of LCD.</AbstractText><CopyrightInformation>&#xa9; The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fenton</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754 New Zealand.</Affiliation><Identifier Source="GRID">grid.420067.7</Identifier><Identifier Source="ISNI">0000 0004 0372 1209</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Arnold</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6519-7831</Identifier><AffiliationInfo><Affiliation>Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754 New Zealand.</Affiliation><Identifier Source="GRID">grid.420067.7</Identifier><Identifier Source="ISNI">0000 0004 0372 1209</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs Ther Perspect</MedlineTA><NlmUniqueID>9308798</NlmUniqueID><ISSNLinking>1172-0360</ISSNLinking></MedlineJournalInfo><CoiStatement>Authorship and conflict of interestC. Fenton, a contracted writer for Adis International Ltd/Springer Nature, and A. Lee, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>19</Day><Hour>4</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36532316</ArticleId><ArticleId IdType="pmc">PMC9742030</ArticleId><ArticleId IdType="doi">10.1007/s40267-022-00975-x</ArticleId><ArticleId IdType="pii">975</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mazza MG, Palladini M, Poletti S, et al. Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs. 2022;36(7):681&#x2013;702. doi: 10.1007/s40263-022-00931-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-022-00931-3</ArticleId><ArticleId IdType="pmc">PMC9210800</ArticleId><ArticleId IdType="pubmed">35727534</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Allan M, Alsokhn C, et al. A clinical case definition of post COVID-19 condition by a Delphi consensus. 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 7 Oct 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the longterm effects of COVID-19 2022. https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742. Accessed 7 Oct 2022.</Citation></Reference><Reference><Citation>Chandra A, Johri A. A peek into Pandora's box: COVID-19 and neurodegeneration. Brain Sci. 2022;12(2):190. doi: 10.3390/brainsci12020190.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci12020190</ArticleId><ArticleId IdType="pmc">PMC8870638</ArticleId><ArticleId IdType="pubmed">35203953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long COVID symptoms after COVID-19 vaccination: community based cohort study. BMJ. 2022;377:e069676. doi: 10.1136/bmj-2021-069676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou GN, Baraff A, Fox A, et al. Rates and factors associated with documentation of diagnostic codes for long COVID in the national Veterans Affairs health care system. JAMA Netw Open. 2022;5(7):e2224359. doi: 10.1001/jamanetworkopen.2022.24359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.24359</ArticleId><ArticleId IdType="pmc">PMC9338411</ArticleId><ArticleId IdType="pubmed">35904783</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Zhou F, Hou W, et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci. 2021;1486(1):90&#x2013;111. doi: 10.1111/nyas.14506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14506</ArticleId><ArticleId IdType="pmc">PMC7675607</ArticleId><ArticleId IdType="pubmed">33009668</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang SW, Leonard BE, Helmeste DM. Long COVID, neuropsychiatric disorders, psychotropics, present and future. Acta Neuropsychiatrica. 2022;34:109&#x2013;126. doi: 10.1017/neu.2022.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/neu.2022.6</ArticleId><ArticleId IdType="pubmed">35144718</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Jia X, Shi H, et al. Prevalence of mental health problems during the COVID-19 pandemic: a systematic review and meta-analysis. J Affect Disord. 2021;15(281):91&#x2013;98. doi: 10.1016/j.jad.2020.11.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.11.117</ArticleId><ArticleId IdType="pmc">PMC7710473</ArticleId><ArticleId IdType="pubmed">33310451</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong F, Liu HL, Dai N, et al. A living systematic review of the psychological problems in people suffering from COVID-19. J Affect Disord. 2021;1(292):172&#x2013;188. doi: 10.1016/j.jad.2021.05.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2021.05.060</ArticleId><ArticleId IdType="pmc">PMC8169237</ArticleId><ArticleId IdType="pubmed">34126309</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, et al. Impact of pre-existing chronic viral infection and reactivation on the development of long COVID. medRxiv [preprint]. 2022. 10.1101/2022.06.21.22276660.</Citation></Reference><Reference><Citation>Foletto VS, da Rosa TF, Serafin MB, et al. Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use. Eur J Clin Pharmacol. 2022;78(10):1601&#x2013;1611. doi: 10.1007/s00228-022-03372-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-022-03372-5</ArticleId><ArticleId IdType="pmc">PMC9360648</ArticleId><ArticleId IdType="pubmed">35943535</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Al-Rubaye HT, Almulla AF, et al. Lowered quality of life in long COVID is predicted by affective symptoms, chronic fatigue syndrome, inflammation and neuroimmunotoxic pathways. Int J Environ Res Public Health. 2022;19(16):10362. doi: 10.3390/ijerph191610362.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191610362</ArticleId><ArticleId IdType="pmc">PMC9408685</ArticleId><ArticleId IdType="pubmed">36011997</ArticleId></ArticleIdList></Reference><Reference><Citation>Vindegaard N, Petersen LV, Lyng-Rasmussen BI, et al. Infectious mononucleosis as a risk factor for depression: a nationwide cohort study. Brain Behav Immun. 2021;94:259&#x2013;265. doi: 10.1016/j.bbi.2021.01.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.01.035</ArticleId><ArticleId IdType="pubmed">33571632</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz BA, Hoertel N, Lenze EJ, et al. Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. Transl Psychiatry. 2022;12:341. doi: 10.1038/s41398-022-02109-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-022-02109-3</ArticleId><ArticleId IdType="pmc">PMC9395392</ArticleId><ArticleId IdType="pubmed">35995770</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetti F, Palladini M, Paolini M, et al. Brain correlates of depression, post-traumatic distress, and inflammatory biomarkers in COVID-19 survivors: a multimodal magnetic resonance imaging study. Brain Behav Immun Health. 2021;18:100387. doi: 10.1016/j.bbih.2021.100387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2021.100387</ArticleId><ArticleId IdType="pmc">PMC8562046</ArticleId><ArticleId IdType="pubmed">34746876</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgognon JM, Cavanagh J. The role of cytokines in modulating learning and memory and brain plasticity. Brain Neurosci Adv. 2020;2020(4):2398212820979802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7750764</ArticleId><ArticleId IdType="pubmed">33415308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, Zanardi R, Palladini M, et al. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol. 2022;54:1&#x2013;6. doi: 10.1016/j.euroneuro.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8500775</ArticleId><ArticleId IdType="pubmed">34634679</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. Temelimab as a disease modifying therapy in patients with neuropsychiatric symptoms in post-COVID 19 or PASC syndrome. 2022. https://www.clinicaltrials.gov/ct2/show/NCT05497089. Accessed 23 Nov 2022.</Citation></Reference><Reference><Citation>Hoertel N, Sanchez-Rico M, Kornhuber J, et al. Antidepressant use and its association with 28-day mortality in inpatients with SARS-CoV-2: support for the FIASMA model against COVID-19. J Clin Med. 2022;2022(11):5882. doi: 10.3390/jcm11195882.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11195882</ArticleId><ArticleId IdType="pmc">PMC9572995</ArticleId><ArticleId IdType="pubmed">36233753</ArticleId></ArticleIdList></Reference><Reference><Citation>Spuch C, Lopez-Garcia M, Rivera-Baltanas T, et al. Efficacy and safety of lithium treatment in SARS-CoV-2 infected patients. Front Pharmacol. 2022;13:850583. doi: 10.3389/fphar.2022.850583.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.850583</ArticleId><ArticleId IdType="pmc">PMC9046673</ArticleId><ArticleId IdType="pubmed">35496309</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>